What this Trial Is About

Researchers are studying high-grade serous ovarian carcinoma (HGSOC) to understand the role of ribosomal protein L8 (RPL8) in this cancer. They found that RPL8 is often amplified in about 30% of HGSOC cases, and its expression is linked to this genetic change. This study aims to explore if RPL8 can serve as a biomarker to assess risk and help guide treatment choices for patients with this type of ovarian cancer. The study will analyze tumor tissue samples from ovarian cancer surgeries, including samples already stored and those yet to be collected. Investigations will involve measuring RPL8, C-MYC, and related genes using laboratory techniques like RT-PCR, ddPCR, Western Blot, and immunohistochemistry. They will also examine gene copy numbers and mutations and study how these genetic factors relate to patient outcomes and treatment responses. Participants will provide tumor tissue samples, and researchers will review medical and clinical data to correlate genetic findings with patient history and outcomes. Statistical tests such as ANOVA, Mann-Whitney, Kruskal-Wallis, Pearson, and Spearman will be used to analyze the data. The primary outcome is the status of RPL8 two years after enrollment, helping to understand its impact over time.

Role of RPL8 Protein Alterations in High-grade Serous Ovarian Carcinoma